Syndax Pharmaceuticals (SNDX) Common Equity (2016 - 2025)
Historic Common Equity for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $115.4 million.
- Syndax Pharmaceuticals' Common Equity fell 6849.89% to $115.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.4 million, marking a year-over-year decrease of 6849.89%. This contributed to the annual value of $288.1 million for FY2024, which is 4801.05% down from last year.
- As of Q3 2025, Syndax Pharmaceuticals' Common Equity stood at $115.4 million, which was down 6849.89% from $157.4 million recorded in Q2 2025.
- Over the past 5 years, Syndax Pharmaceuticals' Common Equity peaked at $554.2 million during Q4 2023, and registered a low of $115.4 million during Q3 2025.
- Its 5-year average for Common Equity is $337.4 million, with a median of $361.9 million in 2022.
- As far as peak fluctuations go, Syndax Pharmaceuticals' Common Equity surged by 32647.97% in 2021, and later plummeted by 6849.89% in 2025.
- Quarter analysis of 5 years shows Syndax Pharmaceuticals' Common Equity stood at $408.4 million in 2021, then rose by 14.47% to $467.4 million in 2022, then rose by 18.56% to $554.2 million in 2023, then crashed by 48.01% to $288.1 million in 2024, then crashed by 59.94% to $115.4 million in 2025.
- Its last three reported values are $115.4 million in Q3 2025, $157.4 million for Q2 2025, and $215.1 million during Q1 2025.